Son Weon-Young, Chung Jin-Tae, Demirtas Ezgi, Holzer Hananel, Sylvestre Camille, Buckett William, Chian Ri-Cheng, Tan Seang Lin
McGill Reproductive Centre, Department of Obstetrics and Gynecology, Royal Victoria Hospital, McGill University, Montreal, Quebec H3A 1A1, Canada.
Reprod Biomed Online. 2008 Jul;17(1):59-67. doi: 10.1016/s1472-6483(10)60294-5.
This study compared the embryological characteristics and clinical outcome of in-vitro maturation (IVM) treatment cycles with and without in-vivo matured oocytes collected following human chorionic gonadotrophin (HCG) priming. The patients were administered 10,000 IU of HCG subcutaneously when endometrial thickness reached > or =6 mm and oocyte collection was performed 35-36 h after HCG administration. The clinical outcome and embryological aspects were analysed between IVM cycles with (group 1) and without (group 2) in-vivo matured oocytes. In group 1, three (range 1-12) in-vivo matured oocytes per patient were retrieved on average. The number of good quality embryos derived from in-vivo matured oocytes in group 1 was significantly higher than those derived from in-vitro matured oocytes in group 1 and group 2 (P < 0.05). However, there was no difference between the number of good quality embryos produced from in-vitro matured oocytes in the two groups. There were 12 clinical pregnancies (40.0%) in group 1, and seven pregnancies (23.3%) in group 2. These results suggest that IVM cycles with in-vivo matured oocytes resulted in a good clinical pregnancy rate, which could be explained by the superior quality of embryos derived from the in-vivo matured oocytes.
本研究比较了在人绒毛膜促性腺激素（HCG）预处理后收集到的有体内成熟卵母细胞和无体内成熟卵母细胞的体外成熟（IVM）治疗周期的胚胎学特征及临床结局。当子宫内膜厚度达到≥6mm时，给患者皮下注射10000IU的HCG，并在注射HCG后35 - 36小时进行卵母细胞采集。分析了有体内成熟卵母细胞的IVM周期（第1组）和无体内成熟卵母细胞的IVM周期（第2组）之间的临床结局和胚胎学情况。在第1组中，每位患者平均回收3个（范围1 - 12个）体内成熟卵母细胞。第1组中由体内成熟卵母细胞产生的优质胚胎数量显著高于第1组和第2组中由体外成熟卵母细胞产生的优质胚胎数量（P < 0.05）。然而，两组中由体外成熟卵母细胞产生的优质胚胎数量没有差异。第1组有12例临床妊娠（40.0%），第2组有7例妊娠（23.3%）。这些结果表明，有体内成熟卵母细胞的IVM周期导致了良好的临床妊娠率，这可以由体内成熟卵母细胞衍生的胚胎的优质来解释。
